Navigation Links
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma. Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while AEterna Zentaris retains rights for the rest of the world.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

"We are very pleased with the FDA's Fast Track designation and we look forward to the emergence of the data from the forthcoming Phase 3 clinical trial in multiple myeloma to be conducted by our partner Keryx, which we hope will establish perifosine as a novel treatment of this serious condition", stated Juergen Engel, Ph.D., President and CEO at AEterna Zentaris. "We further believe that this North American clinical development program will also be very useful to support the development and registration of perifosine for the benefit of patients in the rest of the world."

A Phase 3 trial investigating perifosine in combination with bortezomib (VELCADE(R)) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma is expected to commence by year-end u
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
2. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
3. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
4. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
5. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
6. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
7. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
8. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
10. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
11. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
(Date:7/10/2014)... the University of Illinois at Urbana-Champaign provides new ... of spin and heat at the nanoscale, and ... for data storage and information processing. , ... momentum. In a typical charge current, electrons, spin-angular-momentum ... explained David Cahill, a professor of materials science ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2University of Illinois study advances limits for ultrafast nano-devices 2
... Companies Also Sign Manufacturing and Distribution Agreement, ... 15 Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly ... today that it has reached several,agreements with ... capsules. The third agreement pertains to Omeprazole ...
... April 15 Arbios Systems, Inc.,(OTC Bulletin Board: ... authorization process in the European Union to pursue ... has engaged the British,Standards Institute (BSI), one of ... Company in its effort to obtain a CE ...
... Inc.,today announced the appointment of Fisher HealthCare as the ... the Hitachi, Hitachi,Roche P-Modular and Olympus chemistry analyzers to ... cleared by the U.S.,Food & Drug Administration (FDA) enabling ... The PLAC Test is the only blood test ...
Cached Biology Technology:Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 2Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 3Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 4diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 2diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 3
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... by a discovery about how chickens regulate their appetites. ... the signals sent from its stomach to its brain that ... Poultry farmers often have to restrict food for chickens ... can overeat, affecting their ability to reproduce. The ...
... has shown that obesity runs in families, and twin studies ... heritability estimates over 50%. 32 genes have been identified as ... genes alone cannot fully explain the high level of heritability ... individual differences in childhood body weight. This has led to ...
... to convention, vegetation, when well-maintained, can lower the rates ... robbery and burglary, in cities, according to a Temple ... Evidence from Philadelphia, PA," published in the journal, ... longstanding principle, particularly in urban planning, that you don,t ...
Cached Biology News:Appetite genes are key to better diets for poultry, study shows 2Study finds strong genetic component to childhood obesity 2Urban vegetation deters crime in Philadelphia 2
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
... are based on well-established periodate chemistry, ... and reproducible. This kit contains all ... or antibody, including ready-to-use buffers and ... HRP is supplied ready-to-use and requires ...
... Acridinium NHS ester can be ... nucleic acids. The covalently bound ... chemiluminescence in the presence of ... proteins can be used as ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: